South Korea is quickly increasing its biotech investment through LG Group’s funding of a US cancer therapy company. Recently, LG joined a funding round for Strand Therapeutics, a startup developing mRNA-based cancer treatments. Therefore, this move strengthens South Korea’s position in advanced health technologies.
Strand Therapeutics is based in Massachusetts and was founded by biologists trained at MIT. The company develops cell programming therapies for cancer and rare diseases. Moreover, its technologies aim to treat autoimmune conditions by delivering targeted antigens. South Korea sees this as a powerful step toward leadership in medical innovation.
As a result of the new deal, LG’s total biotech investment now exceeds $50 million. This capital came through LG Technology Ventures, the group’s venture arm. Furthermore, it reflects LG’s ongoing focus on high-growth sectors. Clearly, South Korea views biotech as a long-term pillar of its economy.
LG is also committed to a broader “ABC” strategy—artificial intelligence, bio, and clean tech. Consequently, this investment in biohealth supports multiple sectors. The group believes these areas can create synergies and future value. In turn, this strategy is reshaping South Korea’s innovation goals.
Leadership at LG continues to highlight the role of health technology. The chairman has stressed the value of longer, healthier lives through breakthrough treatments. Additionally, LG’s actions align closely with that vision. Biotech investment is now one of the company’s top priorities.
Previously, LG invested in ADARx Pharmaceuticals, a company targeting rare diseases. In addition, the firm holds stakes in Eko Health, Aetion, and Accellex. These startups offer tools ranging from analytics to wearable diagnostics. Together, they enhance South Korea’s growing biohealth ecosystem.
Artificial intelligence also plays a key role in this shift. For example, LG AI Research recently unveiled Exaone Pass 2.0. This model can detect cancer in under a minute. Therefore, the blend of AI and biotech increases speed and precision in diagnosis.
Overall, South Korea is not limiting its biotech push to funding alone. Instead, it is building an entire platform for health innovation. This includes AI labs, biotech firms, and global partnerships. As the sector grows, South Korea’s international presence will likely rise.
Clearly, biotech investment has become central to South Korea’s global strategy. Through financial support and cross-sector innovation, the country aims to lead in medical technology. Thus, LG’s latest funding move highlights a much larger national ambition.
